Antiplatelet agents may reduce the odds of hepatic fibrosis in patients at risk for chronic liver disease, according to a meta-analysis published in Hepatology International.
To examine the impact of antiplatelet use on hepatic fibrosis progression, study authors conducted a systematic review and meta-analysis using studies identified through a search of Medline, EMBASE, and PubMed from inception to October 2018. The primary outcome evaluated was hepatic fibrosis; a pooled estimate of the odds of hepatic fibrosis with and without antiplatelet therapy was calculated using a fixed-effect generic inverse variance method. Of the total 2310 articles identified, 4 studies (N=3141) were included in the analysis.
Results showed that among patients at risk for chronic liver disease, the likelihood of hepatic fibrosis was reduced by 32% in patients who received antiplatelet agents (adjusted pooled odds ratio [OR] 0.68, 95% CI, 0.56-0.82; P≤ .0001). Regarding potential mechanisms, the authors noted that the anti-inflammatory and antithrombotic effects of antiplatelets likely play a role in hepatic fibrosis prevention.
As the analysis included a limited number of studies, the authors concluded that additional high-quality studies were need to better understand the possible benefits of antiplatelets in the prevention of hepatic fibrosis.
For more information visit springer.com.